Skip to main content

Table 2 Results of HRCT, echocardiography, 6-minute walking test, and blood tests

From: Assessment of novel cardiovascular biomarkers in chronic obstructive pulmonary disease

 

Subjects (n = 120)

Pre-COPD (n = 23)

COPD

(n = 97)

p-value

Chest HRCT

    

 LAA% for the upper lung field (%)

12.3 ± 17.5

2.2 ± 7.9

14.8 ± 18.3

< 0.0001

Echocardiography

    

 LVDd (mm)

46.8 ± 4.5

47.6 ± 3.8

46.2 ± 5.7

0.4452

 EF (%)

67.5 ± 5.3

68.0 ± 4.0

68.5 ± 5.4

0.5705

 E/A

0.80 ± 0.26

1.0 ± 0.3

0.85 ± 0.19

0.0044

 DT (second)

223.8 ± 36.3

219.5 ± 39.3

208.1 ± 25.7

0.6202

 E/E’

8.9 ± 2.1

9.3 ± 1.8

8.2 ± 1.6

0.2055

 RVSP (mmHg)

27.3 ± 6.7

27.7 ± 4.6

24.7 ± 3.4

0.9470

 CO (L/minute)

4.8 ± 0.9

4.7 ± 0.9

4.5 ± 1.3

0.7288

Six-minute walking test

    

 Walking distance (m)

527.5 ± 101.7

558.6 ± 86.4

520.1 ± 104.0

0.1066

 Borg scale

3.4 ± 1.9

2.7 ± 1.8

3.6 ± 1.9

0.0450

 Initiate SpO2 (%)

96.5 ± 1.4

97.1 ± 1.1

96.4 ± 1.4

0.0235

 Minimal SpO2 (%)

91.0 ± 5.5

93.7 ± 3.3

90.3 ± 5.8

0.0026

 Initiate PR (beats/minute)

77.1 ± 11.5

75.0 ± 10.0

77.6 ± 11.8

0.2996

 Maximal PR (beats/minute)

124.0 ± 15.9

126.7 ± 11.7

123.3 ± 16.7

0.2526

Blood test

    

 Gal-3 (pg/mL)

1733.7 ± 4286.3

724.5 ± 780.9

1973.0 ± 4725.8

0.0565

 IL-6 (pg/mL)

2.45 ± 4.41

3.83 ± 9.63

2.12 ± 1.50

0.2297

 CC16 (ng/mL)

9.29 ± 5.69

8.95 ± 3.88

9.38 ± 6.05

0.5462

 sRAGE (pg/mL)

1035.2 ± 554.6

1278.3 ± 721.5

977.6 ± 494.5

0.0500

  1. Data are presented as mean ± SD or number. Boldface indicates a P value with statistical significance. HRCT; high resolution computer tomography, LAA; percentage of low attenuation area, LVDd; left ventricular end-diastolic dimension, EF; ejection fraction, E/A; early diastolic filling velocity/atrial filling velocity ratio, DT; deceleration time, E/E’; early diastolic filling velocity/early diastolic mitral annular velocity, RVSP; right ventricular systolic pressure, CO; cardiac output, SpO2; oxygen saturation, PR; pulse rate, IL-6; interleukin 6, CC16; club cell protein 16, sRAGE; soluble receptor for advanced glycation end products